[LXRX] Lexicon Pharmaceuticals, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 15.18 Change: 0.94 (6.6%)
Ext. hours: Change: 0 (0%)

chart LXRX

Refresh chart

Strongest Trends Summary For LXRX

LXRX is in the medium-term down -55% below S&P in 1 year. In the long-term down -76% below S&P in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatments for human disease. Its drug development programs include LX4211, an orally-delivered small molecule compound that has completed two Phase II clinical trials for the treatment of type 2 diabetes patients, as well as an additional clinical trial for the treatment of type 2 diabetes patients with renal impairment; and completing a Phase II clinical trial for the treatment of type 1 diabetes patients. The company also develops telotristat etiprate or LX1032, an orally-delivered small molecule drug candidate, which has completed two Phase II clinical trials and is in a pivotal Phase III clinical trial for the treatment of carcinoid syndrome and ulcerative colitis. In addition, it develops LX1033, an orally-delivered small molecule compound that has completed Phase II clinical trial for the treatment of irritable bowel syndrome; LX2931, an orally-delivered small molecule compound, which has completed Phase II clinic

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 165.09% Sales Growth - Q/Q-91.66% P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.93% ROE-37.86% ROI
Current Ratio7.45 Quick Ratio Long Term Debt/Equity Debt Ratio0.18
Gross Margin Operating Margin-395.67% Net Profit Margin-400.24% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-830 K Cash From Investing Activities-70.99 M Cash From Operating Activities-23.48 M Gross Profit
Net Profit-28.08 M Operating Profit-26.53 M Total Assets444.68 M Total Current Assets342.31 M
Total Current Liabilities45.93 M Total Debt107.21 M Total Liabilities187.07 M Total Revenue1.79 M
Technical Data
High 52 week13.69 Low 52 week4.36 Last close5.49 Last change-0.36%
RSI67.46 Average true range0.23 Beta1.6 Volume987.44 K
Simple moving average 20 days9.19% Simple moving average 50 days-9.44% Simple moving average 200 days-41.42%
Performance Data
Performance Week2.62% Performance Month20.13% Performance Quart-30.42% Performance Half-48.55%
Performance Year-37.97% Performance Year-to-date-17.32% Volatility daily2.63% Volatility weekly5.87%
Volatility monthly12.03% Volatility yearly41.68% Relative Volume448.21% Average Volume674.2 K
New High New Low

News

2019-06-26 14:07:05 | Here is What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. LXRX

2019-06-13 07:21:54 | Should You Be Pleased About The CEO Pay At Lexicon Pharmaceuticals, Inc.'s NASDAQ:LXRX

2019-06-10 08:07:43 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-06-06 08:06:12 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-06-04 08:06:30 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-06-04 07:00:00 | Lexicon Pharmaceuticals to Present New Clinical Data at 79th American Diabetes Association Scientific Sessions

2019-05-23 07:00:00 | Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

2019-05-08 07:00:00 | Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

2019-05-07 08:03:52 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-05-05 20:13:26 | Here’s What Hedge Funds Think About Lexicon Pharmaceuticals, Inc. LXRX

2019-05-02 17:43:57 | Edited Transcript of LXRX earnings conference call or presentation 1-May-19 12:00pm GMT

2019-05-01 13:16:05 | Lexicon Pharmaceuticals LXRX Reports Q1 Loss, Lags Revenue Estimates

2019-05-01 11:49:47 | Lexicon Pharmaceuticals Inc LXRX Q1 2019 Earnings Call Transcript

2019-05-01 07:30:57 | Lexicon: 1Q Earnings Snapshot

2019-05-01 07:00:00 | Lexicon Pharmaceuticals Reports First Quarter 2019 Financial Results and Provides a Business Update

2019-04-30 08:01:44 | See what the IHS Markit Score report has to say about Lexicon Pharmaceuticals Inc.

2019-04-26 16:02:01 | ZynquistaTM now approved in the European Union for treatment of adults with type 1 diabetes

2019-04-26 16:01:00 | Zynquista™ now Approved in the European Union for Treatment of Adults With Type 1 Diabetes

2019-04-25 10:34:02 | Will Lexicon Pharmaceuticals LXRX Report Negative Q1 Earnings? What You Should Know

2019-04-25 07:00:00 | Lexicon Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call and Webcast on May 1, 2019

2019-04-03 07:07:59 | Did You Manage To Avoid Lexicon Pharmaceuticals's NASDAQ:LXRX Painful 55% Share Price Drop?

2019-04-02 07:00:00 | Lexicon Pharmaceuticals to Present at Upcoming Investor Conference

2019-04-01 14:20:00 | CLASS ACTION UPDATE for LXRX, BRS, WTW and AMR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-04-01 11:20:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

2019-04-01 10:40:00 | FINAL DEADLINE - LXRX Lexicon Pharmaceuticals, Inc. - Bronstein, Gewirtz & Grossman, LLC Reminds Shareholders of Class Action & Deadline: April 1, 2019

2019-03-29 15:00:00 | The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of LXRX, UXIN, AVEO and AMRN

2019-03-29 13:18:29 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

2019-03-28 12:15:00 | CLASS ACTION UPDATE for LXRX, UXIN and CRBP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

2019-03-28 10:43:02 | AstraZeneca's Forxiga Gets Nod in Japan for Type I Diabetes

2019-03-27 10:55:02 | Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL

2019-03-27 10:28:00 | Tyme Technologies, Inc. TYME, Vale S.A. VALE & Lexicon Pharmaceuticals, Inc. LXRX - Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action

2019-03-27 10:00:00 | Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. TYME, Vale S.A. VALE & Lexicon Pharmaceuticals, Inc. LXRX

2019-03-26 16:35:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Lexicon Pharmaceuticals, Inc. To Contact The Firm

2019-03-26 16:05:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - LXRX

2019-03-25 11:05:03 | Lexicon Falls as FDA Denies Approval to Type I Diabetes Drug

2019-03-25 10:10:02 | AstraZeneca's Forxiga Gets EC Approval for Type-I Diabetes

2019-03-25 09:30:33 | What's Next for Lexicon Pharmaceuticals?

2019-03-22 16:46:19 | This Pharma Giant Slipped After FDA Rejected Its Diabetes Treatment

2019-03-22 16:35:00 | Why Zuora, Greenbrier, and Lexicon Pharmaceuticals Slumped Today

2019-03-22 14:39:04 | FDA rejects Sanofi-Lexicon add-on pill for type 1 diabetes

2019-03-22 14:16:02 | Sanofi: FDA issues Complete Response Letter for ZynquistaTM sotagliflozin

2019-03-22 14:16:00 | Lexicon Pharmaceuticals to Host Conference Call and Webcast Today, March 22, 2019 to Provide a Regulatory Update on Sotagliflozin in Type 1 Diabetes

2019-03-22 14:16:00 | FDA Issues Complete Response Letter for Zynquista™ sotagliflozin

2019-03-22 10:39:00 | Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC

2019-03-21 15:00:00 | Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC

2019-03-20 14:44:57 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact the Firm

2019-03-20 10:38:00 | GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder

2019-03-19 19:05:00 | SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Lexicon Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline – LXRX

2019-03-19 16:25:00 | LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing in Lexicon Pharmaceuticals, Inc. to Contact The Firm

2019-03-18 10:36:00 | GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC Class Action